VIVUS Inc. VVUS reported a loss of 6 cents per share in the third quarter ... In fact, so far this year, VIVUS shares have underperformed the industry. The stock declined 43.4% during the period, while the industry witnessed a gain of 3.1%.
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which …
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Thursday's session 2.95% lower at $127.24 with a total trading volume of 1.37 million shares. Over the last month and the previous three months, the …
The average investor's response to VVUS's undesirable statistics is to drop the stock or even short it (you do not short a $2 stock without a good reason). But in this article, I wish to offer a contrarian view, one that seeks VVUS as undervalued.
To say the past couple of months have been uncharacteristically bullish for Vivus, Inc. (VVUS) would be a significant understatement. After spending the past two years losing more than 90% of its value, Vivus stock has rallied an …
VIVUS Inc. VVUS was a big mover last session, as its shares rose a little more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the …
In that article we said the following regarding VVUS stock: VVUS is currently range-bound between the 50-day and 200-day exponential moving averages. If a run-up in VVUS is to occur ahead of the EU approval decision, look for the stock price …